Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - European Market Recap: FTSE 100 (0.28%) to 10720.30, DAX (0.38%) to 26338.61, CAC40 (0.66%) to 8579.60, STOXX 600 (0.22%) to 656.41

Aug 17 ,2026

  • Synopsis:

    • European equity markets closed lower and near session's lowest levels. Last week saw Stoxx 600 record first weekly decline in four weeks. Health Care, Basic Resources and Technology were the best performing sectors. Food & Beverage, Personal and Household Goods and Retail underperformed.

    • Limited fresh catalysts for European markets. Strait of Hormuz standoff continues to underpin European energy risk pricing, but Q2 earnings have been supportive for regional markets. While markets have reduced Fed rate hike expectations, last Friday's backup in rates a point of focus. Analysts and financial press continue to discuss structural pressures, with high debt/borrowing and AI-related corporate supply. European press continues to discuss impact of extreme weather on business activity and productivity.

    • Quiet macro calendar at start of the week. German Economic Institute survey showed German companies have cut investment in the US to a three-year low in H1 2026. S&P Global UK consumer confidence measures weakened. UK employment group CIPD said PM Burnham should partly reverse the national insurance increase and slows plans to equalize minimum wage changes to revive the labor market. UK Rightmove house price update saw biggest drop in August asking prices since 2017.

    • Macro calendar picks up tomorrow with German ZEW and UK labor market update due, while Wednesday sees UK inflation and European PMIs due Friday

    • In corporate news, flatexDEGIRO (FTK.GR) reported final Q2/H1 earnings in line with its preliminary release and reaffirmed its FY guidance. In Switzerland, SIG Combibloc Group (SIGN.SW) appointed Ann-Kristin Erkens as CEO with immediate effect, replacing Mikko Keto. Elsewhere, AstraZeneca (AZN.LN) and argenx (ARGX.BB) reported study results, with the latter trading sharply higher after announcing positive topline results from the Phase 3 ALKIVIA trial of Efgartigimod in autoimmune myositis. Also in the UK, Telecom Plus (TEP.LN) issued an AGM trading statement reaffirming its FY guidance and confirming it's on track to deliver its long-term goal.

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers:

        • Health Care +0.83%, Basic Resources +0.69%, Technology +0.62%, Oil & Gas +0.39%, Financial Svcs (0.07%), Ind Goods & Svcs (0.10%)

      • Underperformers:

        • Food & Beverage (2.32%), Persnl & HHold Goods (2.29%), Retail (2.07%), Media (1.38%), Chemicals (1.21%), Construct & Mtls (1.08%), Real Estate (1.04%), Autos & Parts (0.39%), Utilities (0.36%), Banks (0.31%), Insurance (0.31%), Telecom (0.29%), Travel & Leisure (0.27%)

    • Macro:

      • EU:

        • Plans most far-reaching sanctions package against Russia - Reuters

      • France:

        • PM Lecornu to convene crisis meeting on tax agency cyberattack - Bloomberg

      • Germany:

        • Business climate for residential construction in Germany improves slightly in Jul, ifo survey shows - release

      • Ireland:

        • Government may revisit the timetable for restoring excise cuts on fuel - RTE

      • UK:

        • Burnham faces key test on North Sea oil and gas projects Rosebank and Jackdaw - FT

        • Conservatives aim to reclaim City of London support under Badenoch - Politico

    • Company news:

      • Notable Gainers

        • +17.1% ARGX.BB (argenx €855.20, +125.00) -- Phase 3 ALKIVIA trial of Efgartigimod results

        • +11.2% RAP1V.FH (Rapala VMC €1.54, +0.16)

        • +9.4% HLG.GR (Highlight Communications €0.65, +0.06) -- Estimated weekend box office revenues in US, Canada $160.2M, +76.5% y/y - Box Office Mojo

        • +6.0% TEP.LN (Telecom Plus £9.06, +0.51) -- AGM trading statement

        • +4.7% EVO.SS (Evolution SEK787.60, +35.00) -- ABG Sundal Collier upgrade

        • +4.5% MAERSK.B.DC (Maersk DKK21,630.00, +930.00) -- Arctic Securities upgrade

        • +4.4% CMCX.LN (CMC Markets £7.28, +0.31)

        • +4.2% OHB.GR (OHB SE €270.00, +11.00)

        • +3.6% GMS.LN (Gulf Marine Services £0.20, +0.01) -- small-class vessels contract extension

        • +3.4% SZG.GR (Salzgitter €51.85, +1.70)

        • +2.7% HCM.LN (Hutchmed £1.90, +0.05) -- Orpathys/Tagrisso phase III SAFFRON study results

        • +2.0% HLAG.GR (Hapag-Lloyd €135.00, +2.60)

        • +1.0% RHM.GR (Rheinmetall €1,216.80, +12.00) -- over €500M contract

      • Notable Decliners

        • -17.6% SIGN.SW (SIG Combibloc Group CHF12.74, -2.72) -- new CEO

        • -6.0% BOOZT.SS (Boozt Fashion SEK140.70, -9.00) -- SEB downgrade

        • -2.3% RBREW.DC (Royal Unibrew DKK464.00, -10.80) -- Q2 earnings

        • -2.2% BYLOT.GA (Bally's Intralot €1.15, -0.03) -- prelim. Q2 earnings

        • -2.0% ALVIO.FP (Valerio Therapeutics €0.77, -0.02) -- updates on Etherna Immunotherapies acquisition

    • EU companies reporting tomorrow:

      • Earnings:

        • Benelux: EVS Broadcast Equipment (EVS.BB), Alfen (ALFEN.NA)

        • Denmark: Coloplast (COLO.B.DC)

        • Finland: SAVOX Communications (SAVOX.FH), Gofore (GOFORE.FH), Orthex (ORTHEX.FH)

        • Germany: Einhell Germany (EIN.GR), JDC Group (JDC.GR)

        • Norway: Odfjell Drilling (ODL.NO), Elopak (ELO.NO), Multiconsult (MULTI.NO), Salmon Evolution (SALME.NO),Gigante Salmon (GIGA.NO), Nordhealth (NORDH.NO), Nordic Mining (NOM.NO)

        • Sweden: NOBA Bank Group (NOBA.SS), Alcadon Group (ALCA.SS)

        • Switzerland: PSP Swiss Property (PSPN.SW), HUBER+SUHNER (HUBN.SW), SKAN Group (BVHN.SW), Medartis Holding (MED.SW), Basilea Pharmaceutica (BSLN.SW), Phoenix Mecano (PMN.SW)

        • UK: BHP Group (BHP.LN)

  • Data:

    • Economics:

      • Norway Jul trade balance NOK84.3B vs consensus NOK57.0B, prior revised NOK63.3B from NOK61.9B

      • UK Aug house price index (1.0%) y/y vs prior (0.4%), (2.0%) m/m vs prior (1.0%); now expects 2026 house prices 0%- (2%) vs prior +2% - Rightmove

    • Markets:

      • WTI Crude (Sep 26): +$0.35 or +0.42% to $82.75

      • €-$ +0.0015 or +0.13% to 1.1583

      • £-$ +0.0022 or +0.16% to 1.3555

      • €-£ +0.0003 to 0.8547

      • S&P 500 (0.17%)

      • Performance year-to-date

        • FTSE 100: +7.94%

        • DAX: +7.55%

        • CAC: +5.28%

        • MIB: +19.23%

        • Stoxx 600: +10.84%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.